Scientific Report

Abstract

Tirzepatide is a synthetic peptide analog investigated for dual activity at GIP and GLP-1 receptor pathways. NL-TIRZ is designed for controlled laboratory research into incretin receptor signaling, receptor interaction, glucose pathway modulation, metabolic regulation, lipid metabolism, and downstream cellular responses associated with dual incretin receptor activation.

Mechanistic Pathway

NL-TIRZ is designed around dual incretin receptor pathway modeling.

GIP Receptor Pathway

• Supports research into GIP-associated signaling
  • Used in insulinotropic and metabolic pathway models
  • Helps study receptor interaction in incretin systems

Effect: Provides a model for GIP receptor activity within dual-incretin research systems.

GLP-1 Receptor Pathway

• Supports investigation of incretin signaling
  • Used in glucose-regulatory pathway models
  • Studied for downstream metabolic signaling effects

Effect: Enables research into GLP-1 receptor contribution to dual incretin pathway activity.

Pharmacokinetics / Research Profile

Dosing Models in Research

Used only in controlled in vitro and preclinical research models to study receptor signaling and metabolic pathway response. No human or animal-use instructions are provided.

Preclinical Research Highlights

• Studied as a dual incretin receptor pathway model
  • Used in glucose signaling and metabolic regulation research
  • Supports comparative studies with GLP-1-only and triple-agonist models
  • Relevant to lipid metabolism and insulinotropic pathway studies
  • Useful for evaluating receptor interaction and downstream signaling response

Conclusion

NL-TIRZ offers a research-use-only model for studying dual GIP and GLP-1 receptor pathway activation. Its dual incretin signaling profile supports preclinical investigation into metabolic regulation, glucose pathway signaling, lipid metabolism, receptor interaction, and downstream cellular response models.